Rx (Prescription Medicine)
USD $ 120.00
Tecentriq 840mg 注射液是一种强效的免疫治疗药物，用于治疗某些类型的癌症。其活性成分为 Atezolizumab，这是一种单克隆抗体，旨在靶向并阻断 PD-L1 蛋白。通过抑制 PD-L1，Tecentriq 有助于启动机体自身的免疫系统识别并攻击癌细胞。该药物适用于特定形式的非小细胞肺癌（NSCLC）、小细胞肺癌（SCLC）、尿路上皮癌以及黑色素瘤，通常与其他癌症治疗方案联合使用，或根据癌症类型和分期作为单独治疗使用。典型的剂量和给药方案由医疗专业人员根据患者的具体情况和治疗反应确定。常见的不良反应可能包括疲劳、恶心、腹泻、皮疹以及输液相关反应。虽然较少见，但严重的不良反应可能涉及影响各器官的免疫相关不良事件。Tecentriq 840mg 注射液应储存在室温、避光的环境中，且不可冷冻。务必遵循医生关于用药及操作的指示。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Brand Name | |
| Strength |
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
